Market Overview

UPDATE: Bank of America Downgrades Hospira to Neutral on Cash Flow Guidance

Related HSP
The Medicines Company Falls 10% Following Angiomax Court Hearing
Hospira Issues Statement on FDA Approval of First Biosimilar in US
Neogen Lags Q3 Earnings & Revenue Estimates, Stock Down - Analyst Blog (Zacks)

Bank of America downgraded Hospira (NYSE: HSP) from Buy to Neutral and reduced the price target from $44.00 to $38.00.

Bank of America commented, "HSP announced ‘13 guidance on its 4Q earnings call, and while management's revenue and EPS outlook is roughly consistent with ours, we were disappointed by cash flow guidance. In addition, HSP announced that (1) it is in the midst of deciding on its strategy for remediating its pumps business, which creates some new uncertainty (could have implications for costs and potentially for revenue), and (2) the long-awaited FDA re-inspection of the Rocky Mount facility has just begun, and management plans to summarize the results when complete (guidance assumes a “successful” outcome), potentially within a month or two."

Hospira closed at $34.03 on Tuesday.

Latest Ratings for HSP

Feb 2015Goldman SachsUpgradesSellNeutral
Jan 2015Deutsche BankMaintainsBuy
Dec 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for HSP
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings


Related Articles (HSP)

Around the Web, We're Loving...